32 results on '"M, Hiura"'
Search Results
2. Comparison of the clinical effect of dutasteride therapy for benign prostatic hyperplasia when initiated at different time points: A multicentre, observational, retrospective chart review study
- Author
-
Yukiko Shima, Yoshiaki Kawano, Akihiro Kobayashi, Tomonori Yamanishi, Hirokazu Takeda, Juan Manuel Palacios‐Moreno, Masahiro Yamada, Naoya Masumori, F Fukuta, M Nanri, Y Nishino, K Sagiyama, Y Tsujimoto, Y Arai, H Ohoka, T Yamaguchi, K Nagao, Y Noma, K Suzuki, T Okamoto, Y Enomoto, T Sakuma, I Sakai, H Nagae, S Torii, M Hiura, M Matsushita, E Nozawa, S Kurokawa, Y Mitsui, K Miyakoda, S Kato, K Yoshikawa, Y Kuwahara, H Sakai, N Hagiwara, Y Kasuya, and K Miyamae
- Subjects
medicine.medical_specialty ,business.industry ,Urinary retention ,Medical record ,Incidence (epidemiology) ,Hazard ratio ,General Medicine ,030204 cardiovascular system & hematology ,urologic and male genital diseases ,Dutasteride ,Confidence interval ,law.invention ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,chemistry ,Randomized controlled trial ,law ,Internal medicine ,medicine ,Cumulative incidence ,030212 general & internal medicine ,medicine.symptom ,business - Abstract
Aim To evaluate the effects of early (≤6 months after starting any medical treatment [baseline] for benign prostatic hyperplasia [BPH]), intermediate (between >6 months and 2 years from baseline) and late (2 years after baseline) initiation of add-on dutasteride therapy on the incidence of acute urinary retention (AUR) and BPH-related surgery in Japanese patients with moderate-to-severe BPH. Methods This multicentre, observational, retrospective chart review study used anonymised data from Japanese medical records. Eligible patients (≥50 years) were followed from baseline until first AUR, BPH-related surgery or Year 4. Results Overall, 1206 patients were included (early initiation: n = 793; intermediate: n = 233; late: n = 180). Early dutasteride initiation was not superior to late initiation in reducing the risk of first AUR or BPH-related surgery from baseline (hazard ratio [HR] 0.733; 95% confidence interval [CI] 0.468-1.150) but was superior in reducing the risk of first AUR alone (HR 3.449; 95% CI 1.796-6.623). One year after initiation, the cumulative incidence of first AUR rose rapidly in the late vs early and intermediate initiation groups. Incidences of all parameters (first AUR/BPH-related surgery, first AUR alone and BPH-related surgery alone) in patients undergoing BPH-related surgery in low incidence sites (ie clinical sites with ≤ 16% incidence of first AUR or BPH-related surgery) were significantly lower in the early vs late initiation groups. Conclusion Early dutasteride initiation reduced the risk of AUR in a Japanese real-world setting. A randomised controlled trial is warranted to evaluate the benefit of early initiation in preventing BPH-related surgery in Japanese patients.
- Published
- 2019
3. Statement of FISA sports medicine commission: biological effects of testosterone
- Author
-
KE Ackerman, J. Hannafin, JM Steinacker, A Lacoste, P. Zupet, M. Hiura, T. Smoljanovic, P. Poli, M. Wilkinson, D. Koubaa, and H. B. Nielsen
- Subjects
medicine.medical_specialty ,Sports medicine ,Statement (logic) ,Law ,medicine ,Physical Therapy, Sports Therapy and Rehabilitation ,Orthopedics and Sports Medicine ,Testosterone (patch) ,Commission ,Psychology - Published
- 2019
- Full Text
- View/download PDF
4. List of Contributors
- Author
-
P. Alvarez-Suarez, S. Anand, A.L. Aral, A. Begega, R. Beurskens, S. Bonavita, R.W. Cohen, M. Cowan, A. Cruz, M. Cuesta, M. Dalecki, W.C. Damasceno, J. Díaz-Castro, M.J. Fannon-Pavlich, C.G. Fonseca, H. Hasegawa, R.A. Hernandez, M.M. Herting, S. Hijano, M. Hiura, R.M. Ichiyama, N. Kajarabille, M.F. Keenan, A.C. Kunstetter, N. Leelayuwat, C.D. Mandyam, R.N. Martins, J. Moreno-Fernández, T. Nariai, J.J. Ochoa, R.V. Pedroso, S. Perrey, L. Pinar, G.A. Prieto, M. Pulido-Morán, T. Ravikiran, P. Sampedro-Piquero, B. Sehm, T.M. Shah, M.S. Shanmugam, S. Snigdha, S.S. Somkuwar, A.M. Stein, G. Tedeschi, W.M. Tierney, T.L. Uhlendorf, R. Vani, S.P. Wanner, J. Watson, K.E. Welman, A. Yoder, and X. Zheng
- Published
- 2017
- Full Text
- View/download PDF
5. Statement of FISA Sports Medicine Commission: Biological Effects of Testosterone.
- Author
-
J. M., Steinacker, D., Koubaa, H. B., Nielsen, J., Hannafin, M., Hiura, P., Poli, T., Smoljanovic, M., Wilkinson, P., Zupet, A., Lacoste, and K. E., Ackerman
- Subjects
SPORTS medicine ,PHYSIOLOGICAL effects of testosterone - Published
- 2019
- Full Text
- View/download PDF
6. Beyond MABEL: An Integrative Approach to First in Human Dose Selection of Immunomodulators by the Health and Environmental Sciences Institute (HESI) Immuno-Safety Technical Committee (ITC).
- Author
-
Matsumoto M, Polli JR, Swaminathan SK, Datta K, Kampershroer C, Fortin MC, Salian-Mehta S, Dave R, Yang Z, Arora P, Hiura M, Suzuki M, Brennan FR, and Sathish J
- Subjects
- Humans, Drug Development methods, Dose-Response Relationship, Drug, Immunologic Factors administration & dosage, Immunologic Factors adverse effects, Risk Assessment, Advisory Committees, Immunomodulating Agents pharmacology
- Abstract
Administration of a new drug candidate in a first-in-human (FIH) clinical trial is a particularly challenging phase in drug development and is especially true for immunomodulators, which are a diverse and complex class of drugs with a broad range of mechanisms of action and associated safety risks. Risk is generally greater for immunostimulators, in which safety concerns are associated with acute toxicity, compared to immunosuppressors, where the risks are related to chronic effects. Current methodologies for FIH dose selection for immunostimulators are focused primarily on identifying the minimum anticipated biological effect level (MABEL), which has often resulted in sub-therapeutic doses, leading to long and costly escalation phases. The Health and Environmental Sciences Institute (HESI) - Immuno-Safety Technical Committee (ITC) organized a project to address this issue through two complementary approaches: (i) an industry survey on FIH dose selection strategies and (ii) detailed case studies for immunomodulators in oncology and non-oncology indications. Key messages from the industry survey responses highlighted a preference toward more dynamic PK/PD approaches as in vitro assays are seemingly not representative of true physiological conditions for immunomodulators. These principles are highlighted in case studies. To address the above themes, we have proposed a revised decision tree, which expands on the guidance by the IQ MABEL Working Group (Leach et al. 2021). This approach facilitates a more refined recommendation of FIH dose selection for immunomodulators, allowing for a nuanced consideration of their mechanisms of action (MOAs) and the associated risk-to-benefit ratio, among other factors., (© 2024 The Author(s). Clinical Pharmacology & Therapeutics published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.)
- Published
- 2024
- Full Text
- View/download PDF
7. Editorial: Model organisms and experimental models: opportunities and challenges in clinical and translational physiology.
- Author
-
Myslivecek J, Lung CW, Martins-Marques T, Orange ST, Hiura M, and Ding Y
- Abstract
Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
- Published
- 2023
- Full Text
- View/download PDF
8. Global Alliance for the Promotion of Physical Activity: the Hamburg Declaration.
- Author
-
Steinacker JM, van Mechelen W, Bloch W, Börjesson M, Casasco M, Wolfarth B, Knoke C, Papadopoulou T, Wendt J, Al Tunaiji H, Andresen D, Andrieieva O, Bachl N, Badtieva V, Beucher FJ, Blauwet CA, Casajus Mallen JA, Chang JH, Clénin G, Constantini N, Constantinou D, Di Luigi L, Declercq L, Doutreleau S, Drozdovska S, Duclos M, Ermolao A, Fischbach T, Fischer AN, Fossati C, Franchella J, Fulcher M, Galle JC, Gerloff C, Georgiades E, Gojanovic B, González Gross M, Grote A, Halle M, Hauner H, Herring MP, Hiura M, Holze K, Huber G, Hughes D, Hutchinson MR, Ionescu A, Janse van Rensburg DC, Jegier A, Jones N, Kappert-Gonther K, Kellerer M, Kimura Y, Kiopa A, Kladny B, Koch G, Kolle E, Kolt G, Koutedakis Y, Kress S, Kriemler S, Kröger J, Kuhn C, Laszlo R, Lehnert R, Lhuissier FJ, Lüdtke K, Makita S, Manonelles Marqueta P, März W, Micallef-Stafrace K, Miller M, Moore M, Müller E, Neunhäuserer D, Onur IR, Ööpik V, Perl M, Philippou A, Predel HG, Racinais S, Raslanas A, Reer R, Reinhardt K, Reinsberger C, Rozenstoka S, Sallis R, Sardinha LB, Scherer M, Schipperijn J, Seil R, Tan B, Schmidt-Trucksäss A, Schumacher N, Schwaab B, Schwirtz A, Suzuki M, Swart J, Tiesler R, Tippelt U, Tillet E, Thornton J, Ulkar B, Unt E, Verhagen E, Weikert T, Vettor R, Zeng S, Budgett R, Engebretsen L, Erdener U, Pigozzi F, and Pitsiladis YP
- Abstract
Non-communicable diseases (NCDs), including coronary heart disease, stroke, hypertension, type 2 diabetes, dementia, depression and cancers, are on the rise worldwide and are often associated with a lack of physical activity (PA). Globally, the levels of PA among individuals are below WHO recommendations. A lack of PA can increase morbidity and mortality, worsen the quality of life and increase the economic burden on individuals and society. In response to this trend, numerous organisations came together under one umbrella in Hamburg, Germany, in April 2021 and signed the 'Hamburg Declaration'. This represented an international commitment to take all necessary actions to increase PA and improve the health of individuals to entire communities. Individuals and organisations are working together as the 'Global Alliance for the Promotion of Physical Activity' to drive long-term individual and population-wide behaviour change by collaborating with all stakeholders in the community: active hospitals, physical activity specialists, community services and healthcare providers, all achieving sustainable health goals for their patients/clients. The 'Hamburg Declaration' calls on national and international policymakers to take concrete action to promote daily PA and exercise at a population level and in healthcare settings., Competing Interests: Competing interests: EV is Editor in Chief of BMJ Open Sports & Exercise Medicine., (© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2023
- Full Text
- View/download PDF
9. Dissociated coupling between cerebral oxygen metabolism and perfusion in the prefrontal cortex during exercise: a NIRS study.
- Author
-
Hiura M, Funaki A, Shibutani H, Takahashi K, and Katayama Y
- Abstract
Purpose: The present study used near-infrared spectroscopy to investigate the relationships between cerebral oxygen metabolism and perfusion in the prefrontal cortex (PFC) during exercises of different intensities. Methods: A total of 12 recreationally active men (age 24 ± 6 years) were enrolled. They performed 17 min of low-intensity exercise (ExL), followed by 3 min of moderate-intensity exercise (ExM) at constant loads. Exercise intensities for ExL and ExM corresponded to 30% and 45% of the participants' heart rate reserve, respectively. Cardiovascular and respiratory parameters were measured. We used near-infrared time-resolved spectroscopy (TRS) to measure the cerebral hemoglobin oxygen saturation (ScO
2 ) and total hemoglobin concentration ([HbT]), which can indicate the cerebral blood volume (CBV). As the cerebral metabolic rate for oxygen (CMRO2 ) is calculated using cerebral blood flow (CBF) and ScO2 , we assumed a constant power law relationship between CBF and CBV based on investigations by positron emission tomography (PET). We estimated the relative changes in CMRO2 (rCMRO2 ) and CBV (rCBV) from the baseline. During ExL and ExM, the rate of perceived exertion was monitored, and alterations in the subjects' mood induced by exercise were evaluated using the Profile of Moods Scale-Brief. Results: Three minutes after exercise initiation, ScO2 decreased and rCMRO2 surpassed rCBV in the left PFC. When ExL changed to ExM, cardiovascular variables and the sense of effort increased concomitantly with an increase in [HbT] but not in ScO2 , and the relationship between rCMRO2 and rCBV was dissociated in both sides of the PFC. Immediately after ExM, [HbT], and ScO2 increased, and the disassociation between rCMRO2 and rCBV was prominent in both sides of the PFC. While blood pressure decreased and a negative mood state was less prominent following ExM compared with that at rest, ScO2 decreased 15 min after exercise and rCMRO2 surpassed rCBV in the left PFC. Conclusion: Dissociated coupling between cerebral oxidative metabolism and perfusion in the PFC was consistent with the effort required for increased exercise intensity and associated with post-exercise hypotension and altered mood status after exercise. Our result demonstrates the first preliminary results dealing with the coupling between cerebral oxidative metabolism and perfusion in the PFC using TRS., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2023 Hiura, Funaki, Shibutani, Takahashi and Katayama.)- Published
- 2023
- Full Text
- View/download PDF
10. Short stature as an initial presenting presentation of unicentric Castleman disease in a child: A case report with long-term follow-up and a literature review.
- Author
-
Sonoda K, Kaneko U, Hiura M, Kinoshita Y, Umezu H, Ito S, Saitoh A, and Imai C
- Subjects
- Female, Humans, Child, Follow-Up Studies, Diagnosis, Differential, Fever, Castleman Disease complications, Castleman Disease diagnosis
- Abstract
Short stature is a common clinical condition in paediatric outpatient clinics and is associated with various clinical conditions, ranging from normal variants to severe diseases. Short stature is known to be caused by chronic inflammatory conditions, in which over-produced inflammatory cytokines are reported to be involved in growth suppression. Castleman disease is a rare lymphoproliferative disorder known as a chronic inflammatory disease with overproduction of interleukin 6, which often causes systemic symptoms such as fever, fatigue, weight loss, and night sweats. Here, we report the case of a 10-year-old female diagnosed with unicentric Castleman disease, who presented with short stature as the sole clinical sign but lacked typical systemic symptoms of Castleman disease. An elevated serum C-reactive protein level led us to suspect a chronic inflammatory condition, and we found an intra-abdominal tumour that was histopathologically confirmed as Castleman disease. The tumour removal resulted in a steady catch-up in her height in the six years following the surgery. We also present a brief review of relevant literature on paediatric cases of Castleman disease associated with growth impairment. Clinicians should be aware that chronic inflammatory conditions can cause growth impairment, which may be a key clinical manifestation of such conditions., (© Japan College of Rheumatology 2022. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2023
- Full Text
- View/download PDF
11. Clinical evaluation of the cobas® MTB-RIF/INH reagent and the cobas® 6800 for the detection of isoniazid and rifampicin resistance.
- Author
-
Aono A, Murase Y, Minegishi M, Ohtawa S, Yano M, Chikamatsu K, Shimomura Y, Hosoya M, Igarashi Y, Morishige Y, Yamada H, Takaki A, Togashi K, Hiura M, and Mitarai S
- Subjects
- Humans, Indicators and Reagents, Isoniazid pharmacology, Microbial Sensitivity Tests, Rifampin pharmacology, Sensitivity and Specificity, Mycobacterium tuberculosis, Tuberculosis, Multidrug-Resistant diagnosis, Tuberculosis, Multidrug-Resistant drug therapy, Tuberculosis, Multidrug-Resistant microbiology
- Abstract
We aimed to validate the performance of a newly developed real-time PCR assay using cobas® MTB-RIF/INH reagent on the cobas® 6800 system for detecting isoniazid (INH) and rifampicin (RIF) resistance, using Japanese Mycobacterium tuberculosis (MTB) isolates. In total, 119 mock sputum specimens spiked with resistant MTB were tested using the cobas® MTB-RIF/INH reagent. The whole genomes of all MTB isolates were sequenced by MiSeq and analysed for mutations/indels causing drug resistance. All isolates were tested for phenotypic drug susceptibility, then MTB negative sputa were collected and pooled to prepare mock sputum specimens for the study. The sensitivity and specificity for INH resistance at a concentration equal to 3 × the limit of detection were 77.8% and 90.0%, respectively; those for RIF resistance were 91.8% and 93.5%, respectively. The sensitivities for INH and RIF were statistically different (P = 0.014), but not the specificities (P = 0.624). Twenty-two false-susceptible and two false-resistant results were obtained in INH; meanwhile, six false-susceptible and three false-resistant results were obtained in RIF. False-resistance for INH and RIF was mainly due to disputed mutations. The cobas® MTB-RIF/INH reagent showed better performance than other rapid molecular tests., (Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
12. Estimation of Cerebral Hemodynamics and Oxygenation During Various Intensities of Rowing Exercise: An NIRS Study.
- Author
-
Hiura M, Shirai Y, Shibutani H, Funaki A, Takahashi K, and Katayama Y
- Abstract
Purpose: This study aimed to investigate changes in cerebral hemodynamics and oxygenation at moderate, heavy, maximal and supramaximal intensities of rowing exercise. It also examined whether these changes reflect alterations in sensation of effort and mood. We also aimed to examine the effects of peak pulmonary oxygen consumption ( V . O
2p eak ) on cerebral oxygenation., Methods: Eleven rowers, consisting out of six athletes and five recreational rowers [two female; age, 27 ± 9 years; height, 171 ± 7 cm, body mass, 67 ± 9 kg; V . O2p eak , 53.5 ± 6.5 mL min-1 kg-1 ] rowed a 13-min session separated by 10 and 3 min, at 70 (Ex70% ) and 80% of V . O2p eak (Ex80% ), respectively, on a rowing ergometer, followed by three sessions of 1-min supramaximal exercise (ExSp). After a warm-up at 60% of V . O2p eak (ExM), seven male rowers performed a 2,000 m all-out test (Ex2000 ). Cardiovascular and respiratory variables were measured. Cerebral oxygenation was investigated by near-infrared time-resolved spectroscopy (TRS) to measure cerebral hemoglobin oxygen saturation (ScO2 ) and total hemoglobin concentration ([HbT]) in the prefrontal cortex (PFC) quantitatively. We estimated the relative changes from rest in cerebral metabolic rate for oxygen (rCMRO2 ) using TRS at all intensities. During Ex70% and Ex80% , ratings of perceived exertion (RPE) were monitored, and alteration of the subject's mood was evaluated using a questionnaire of Positive-and-Negative-Affect-Schedule after Ex70% and Ex80% ., Results: When exercise intensity changed from Ex70% to Ex80% , the sense of effort increased while ScO2 decreased. [HbT] remained unchanged. After Ex70% and Ex80% , a negative mood state was less prominent compared to rest and was accompanied by increases in both ScO2 and [HbT]. At termination of Ex2000 , ScO2 decreased by 23% compared to rest. Changes in ScO2 correlated with V . O2p eak only during Ex2000 ( r = -0.86; p = 0.01). rCMRO2 did not decrease at any intensities., Conclusion: Our results suggest that alterations in the sense of effort are associated with oxygenation in the PFC, while positive changes in mood status are associated with cerebral perfusion and oxygen metabolism estimated by TRS. At exhaustion, the cerebral metabolic rate for oxygen is maintained despite a decrease in ScO2 ., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Hiura, Shirai, Shibutani, Funaki, Takahashi and Katayama.)- Published
- 2022
- Full Text
- View/download PDF
13. Effect of direct-acting antivirals on platelet-associated immunoglobulin G and thrombocytopenia in hepatitis C virus-related chronic liver disease.
- Author
-
Honma Y, Shibata M, Hayashi T, Kusanaga M, Ogino N, Minami S, Kumei S, Oe S, Miyagawa K, Senju M, Matsuoka H, Watanabe T, Hiura M, Abe S, and Harada M
- Subjects
- Aged, Female, Hepatitis C, Chronic blood, Humans, Liver Cirrhosis blood, Liver Function Tests, Logistic Models, Male, Middle Aged, Prospective Studies, Sustained Virologic Response, Antiviral Agents therapeutic use, Hepatitis C, Chronic drug therapy, Immunoglobulin G blood, Platelet Count, Thrombocytopenia blood
- Abstract
Background & Aims: Hepatitis C virus (HCV) infection has been known to cause various extrahepatic autoimmune disorders. The prevalence of platelet-associated immunoglobulin G (PA-IgG) has been high in patients with HCV infection. Because thrombocytopenia in HCV-related liver diseases is a notable problem, we performed prospective study on the effect of direct-acting antivirals (DAAs) treatment on PA-IgG and platelet count., Methods: A total of 215 patients with HCV-related liver disease were enrolled in this study. The patients who discontinued DAAs or did not undergo adequate laboratory examinations and who did not achieve sustained virologic response were excluded and finally a total of 187 patients were investigated., Results: A total of 171 patients (91.4%) were PA-IgG positive (>46 ng/10
7 cells) before starting DAAs (baseline). The PA-IgG level elevation was significantly correlated with higher liver inflammation and fibrosis markers (P < 0.05) and lower platelet count (P = 0.000019). The platelet count of the patients with low PA-IgG titer tended to be higher at baseline, end of treatment (EOT), and at 12 and 24 weeks after EOT. The platelet count increased at EOT (P < 0.05) and 24 weeks after EOT (P < 0.01). The PA-IgG levels were significantly decreased at EOT, 12 and 24 weeks after EOT (P < 0.01). Multiple regression analysis found that only platelet count at baseline was closely associated with negative conversion of PA-IgG at 24 weeks after EOT (P = 0.004)., Conclusions: Eradication of HCV by DAAs treatment successfully decreased PA-IgG level and increased platelet count., (© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)- Published
- 2019
- Full Text
- View/download PDF
14. Mogamulizumab Treatment Elicits Autoantibodies Attacking the Skin in Patients with Adult T-Cell Leukemia-Lymphoma.
- Author
-
Suzuki Y, Saito M, Ishii T, Urakawa I, Matsumoto A, Masaki A, Ito A, Kusumoto S, Suzuki S, Hiura M, Takahashi T, Morita A, Inagaki H, Iida S, and Ishida T
- Subjects
- Adult, Antineoplastic Agents adverse effects, Autoantibodies drug effects, Complement System Proteins immunology, Cytotoxicity, Immunologic drug effects, Humans, Keratinocytes drug effects, Keratinocytes pathology, Leukemia-Lymphoma, Adult T-Cell pathology, Lymphocyte Depletion, Receptors, CCR4 antagonists & inhibitors, Receptors, CCR4 metabolism, Skin Diseases chemically induced, Skin Diseases pathology, T-Lymphocytes, Regulatory drug effects, T-Lymphocytes, Regulatory immunology, Antibodies, Monoclonal, Humanized adverse effects, Autoantibodies immunology, Cytotoxicity, Immunologic immunology, Keratinocytes immunology, Leukemia-Lymphoma, Adult T-Cell drug therapy, Leukemia-Lymphoma, Adult T-Cell immunology, Skin Diseases immunology
- Abstract
Purpose: The anti-CCR4 mAb, mogamulizumab, offers therapeutic benefit to patients with adult T-cell leukemia-lymphoma (ATL), but skin-related adverse events (AE) such as erythema multiforme occur frequently. The purpose of this study was to determine the mechanisms by which mogamulizumab causes skin-related AEs in patients with ATL., Experimental Design: We investigated whether autoantibodies were present in patients' sera using flow cytometry to determine binding to keratinocytes and melanocytes ( n = 17), and immunofluorescence analysis of tissue sections. We analyzed the IgM heavy chain repertoire in peripheral blood mononuclear cells before and after mogamulizumab or other chemotherapy by next-generation sequencing (NGS; n = 16)., Results: Autoantibodies recognizing human keratinocytes or melanocytes were found in the sera of 6 of 8 patients suffering from mogamulizumab-induced erythema multiforme. In one patient, complement-dependent cytotoxicity (CDC) mediated by autoantibodies against keratinocytes or melanocytes was proportionally related to the severity of the erythema multiforme. The presence of autoantibodies in the epidermis was confirmed in all biopsy specimens of mogamulizumab-induced erythema multiforme ( n = 12). Furthermore, colocalization of autoantibodies and C1q, suggesting the activation of CDC, was observed in 67% (8/12). In contrast, no autoantibody or C1q was found in ATL tumor skin lesions ( n = 13). Consistent with these findings, NGS demonstrated that IgM germline genes had newly emerged and expanded, resulting in IgM repertoire skewing at the time of erythema multiforme., Conclusions: Mogamulizumab elicits autoantibodies playing an important role in skin-related AEs, possibly associated with regulatory T-cell depletion. This is the first report demonstrating the presence of skin-directed autoantibodies after mogamulizumab treatment., (©2019 American Association for Cancer Research.)
- Published
- 2019
- Full Text
- View/download PDF
15. Hyperammonemia in a Woman with Late-onset Ornithine Transcarbamylase Deficiency.
- Author
-
Koya Y, Shibata M, Senju M, Honma Y, Hiura M, Ishii M, Matsumoto S, and Harada M
- Subjects
- Adolescent, Amino Acids blood, Ammonia blood, Arginine therapeutic use, Coma etiology, Female, Humans, Middle Aged, Mutation, Ornithine Carbamoyltransferase genetics, Ornithine Carbamoyltransferase Deficiency Disease diagnosis, Ornithine Carbamoyltransferase Deficiency Disease drug therapy, Ornithine Carbamoyltransferase Deficiency Disease genetics, Pedigree, Vomiting etiology, Hyperammonemia etiology, Ornithine Carbamoyltransferase Deficiency Disease complications
- Abstract
A 52-year-old woman developed vomiting and disturbance of consciousness after consuming raw fish and sushi on a trip. A blood test showed hyperammonemia (310 μg/dL) with a normal liver function. She fell into a deep coma, and her serum ammonia level increased to 684 μg/dL. L-arginine was administered as a diagnostic treatment for urea cycle disorder (UCD) and serum ammonia, and her consciousness levels improved. She was diagnosed with ornithine transcarbamylase deficiency (OTCD) by analyses of plasma amino acids, urinary orotic acid, and the OTC gene mutation. UCD should be considered for patients with hyperammonemia without severe liver function abnormalities.
- Published
- 2019
- Full Text
- View/download PDF
16. Chimeric Mice With Humanized Livers Demonstrate Human-Specific Hepatotoxicity Caused by a Therapeutic Antibody Against TRAIL-Receptor 2/Death Receptor 5.
- Author
-
Nihira K, Nan-Ya KI, Kakuni M, Ono Y, Yoshikawa Y, Ota T, Hiura M, and Yoshinari K
- Subjects
- Animals, Biomarkers blood, Chemical and Drug Induced Liver Injury metabolism, Chemical and Drug Induced Liver Injury pathology, Chimera, Dose-Response Relationship, Drug, Gene Expression drug effects, Hepatocytes drug effects, Hepatocytes pathology, Hepatocytes transplantation, Humans, Liver metabolism, Liver pathology, Liver Function Tests, Male, Mice, Mice, SCID, Mice, Transgenic, Antibodies, Monoclonal toxicity, Chemical and Drug Induced Liver Injury etiology, Liver drug effects, Receptors, TNF-Related Apoptosis-Inducing Ligand antagonists & inhibitors
- Abstract
The activation of tumor necrosis factor (TNF)-related apoptosis-inducing ligand receptor 2 (TRAIL-R2)/death receptor 5 (DR5) induces apoptosis in various tumor cells but not in normal human cells. Because some therapeutic antibodies targeting TRAIL-R2 have demonstrated severe hepatotoxicity in clinical applications, novel in vivo models reflecting clinical hepatotoxicity are now required. In this study, we investigated the hepatotoxicity caused by KMTR2, an anti-human TRAIL-R2 monoclonal antibody, in chimeric mice with humanized livers (PXB-mice). PXB-mice were exposed to KMTR2 by single or repeated (weekly for 4 weeks) intravenous administrations, and the analyses of blood chemistry, liver histopathology, hepatic gene expression, and toxicokinetics were performed. Treatment with 1 or 10 mg/kg of KMTR2 increased alanine transaminase (ALT) activity and human ALT1 levels in blood. Histopathological analysis revealed that cell death and degeneration with the infiltration of inflammatory cells in human but not mouse hepatocytes were increased in a time-dependent manner after KMTR2 administration. Furthermore, increases in TdT-mediated dUTP nick end labeling (TUNEL)-positive human hepatocytes and serum concentration of cleaved cytokeratin 18, a human-specific apoptosis marker, were observed. RNA sequence analysis showed that the gene expression profile changed in different manners between human and mouse hepatocytes and the up-regulation of TRAIL-R2-related genes was observed only in human hepatocytes. Taken together, these results indicate that KMTR2-mediated TRAIL-R2 activation induces apoptosis of human hepatocytes and hepatotoxicity in PXB-mice and suggest that chimeric mice with humanized liver can be novel tools for the evaluation of in vivo human-specific hepatotoxicity induced by therapeutic antibodies in pre-clinical studies.
- Published
- 2019
- Full Text
- View/download PDF
17. A Young Adult Patient with Nonalcoholic Steatohepatitis Developed Severe Gastroesophageal Varices Associated with Severe Obesity and Diabetes Mellitus.
- Author
-
Honma Y, Sumida K, Ogino N, Kusanaga M, Minami S, Kumei S, Matsuoka H, Watanabe T, Hiura M, Abe S, Shibata M, and Harada M
- Abstract
Obesity is a major contributor to insulin resistance and nonalcoholic fatty liver disease, which is the most common cause of chronic liver diseases. Nonalcoholic steatohepatitis (NASH) can progress to liver cirrhosis and end-stage liver diseases. Some cases already show severe liver fibrosis at the time of diagnosis. We present the case of a 44-year-old male with overt obesity who was admitted with hematemesis due to the rupture of gastric varices. We diagnosed him with NASH with severe liver fibrosis. This case shows that we should be concerned about the progression of liver fibrosis due to NASH associated with severe obesity even in young patients.
- Published
- 2018
- Full Text
- View/download PDF
18. Response of Cerebral Blood Flow and Blood Pressure to Dynamic Exercise: A Study Using PET.
- Author
-
Hiura M, Nariai T, Sakata M, Muta A, Ishibashi K, Wagatsuma K, Tago T, Toyohara J, Ishii K, and Maehara T
- Subjects
- Brain blood supply, Brain Mapping, Brain Stem blood supply, Brain Stem diagnostic imaging, Cerebellar Vermis blood supply, Cerebellar Vermis diagnostic imaging, Cerebral Cortex blood supply, Cerebral Cortex diagnostic imaging, Humans, Image Processing, Computer-Assisted, Male, Oxygen Radioisotopes, Pons blood supply, Pons diagnostic imaging, Sensorimotor Cortex blood supply, Sensorimotor Cortex diagnostic imaging, Temporal Lobe blood supply, Temporal Lobe diagnostic imaging, Thalamus blood supply, Thalamus diagnostic imaging, Young Adult, Blood Pressure physiology, Brain diagnostic imaging, Cerebrovascular Circulation physiology, Exercise physiology, Positron-Emission Tomography methods
- Abstract
Dynamic exercise elicits fluctuations in blood pressure (BP) and cerebral blood flow (CBF). This study investigated responses in BP and CBF during cycling exercise and post-exercise hypotension (PEH) using positron emission tomography (PET). CBF was measured using oxygen-15-labeled water (H
2 15 O) and PET in 11 human subjects at rest (Rest), at the onset of exercise (Ex1), later in the exercise (Ex2), and during PEH. Global CBF significantly increased by 13% at Ex1 compared with Rest, but was unchanged at Ex2 and during PEH. Compared with at Rest, regional CBF (rCBF) increased at Ex1 (20~42%) in the cerebellar vermis, sensorimotor cortex for the bilateral legs (M1Leg and S1Leg ), insular cortex and brain stem, but increased at Ex2 (28~31%) only in the vermis and M1Leg and S1Leg . During PEH, rCBF decreased compared with Rest (8~13%) in the cerebellum, temporal gyrus, piriform lobe, thalamus and pons. The areas showing correlations between rCBF and mean BP during exercise and PEH were consistent with the central autonomic network, including the brain stem, cerebellum, and hypothalamus (R2 =0.25-0.64). The present study suggests that higher brain regions are coordinated through reflex centers in the brain stem in order to regulate the cardiovascular response to exercise., Competing Interests: The authors have no conflicts of interest to declare., (© Georg Thieme Verlag KG Stuttgart · New York.)- Published
- 2018
- Full Text
- View/download PDF
19. Dynamic Exercise Elicits Dissociated Changes Between Tissue Oxygenation and Cerebral Blood Flow in the Prefrontal Cortex: A Study Using NIRS and PET.
- Author
-
Hiura M, Nariai T, Takahashi K, Muta A, Sakata M, Ishibashi K, Toyohara J, Wagatsuma K, Tago T, Ishii K, and Maehara T
- Subjects
- Humans, Magnetic Resonance Imaging methods, Male, Positron-Emission Tomography methods, Spectroscopy, Near-Infrared methods, Young Adult, Cerebrovascular Circulation physiology, Exercise physiology, Oxygen Consumption physiology, Prefrontal Cortex blood supply
- Abstract
Neuronal activity causes changes in both cerebral metabolic rate of oxygen (CMRO
2 ) and cerebral blood flow (CBF). Since the relationship between tissue oxygenation and regional CBF (rCBF) during exercise has not been elucidated, we compared the data obtained using near-infrared spectroscopy (NIRS) and rCBF examined using positron emission tomography (PET). Participants in this study comprised 26 healthy young men. Changes in concentration of oxygenated hemoglobin (ΔO2 Hb) and deoxygenated hemoglobin (ΔHHb) in the prefrontal cortex (PFC) were measured using NIRS continuously during a 15-min bout of the constant-load low-intensity cycling exercise (n = 14). Under the same protocol as the NIRS study, rCBF was measured using H2 15 O and PET by the autoradiographic method at baseline (Rest) and at 3 min (Ex1) and 13 min (Ex2) after starting exercise (n = 12). As systematic factors influenced by exercise, heart rate, end-tidal pressure of carbon dioxide (PET CO2 ) and blood pressure (BP) were monitored. For each region investigated by NIRS, rCBF was analyzed quantitatively using PET-MRI co-registered standardized images. Despite inter-individual differences, changing patterns of ΔO2 Hb and ΔHHb in the PFC were similar between channels. Significant main effects for time point were identified in ΔO2 Hb, ΔHHb and changes in rCBF. While rCBF increased from rest, ΔO2 Hb was not changed at Ex1. Conversely, rCBF was unchanged from rest but ΔO2 Hb was significantly increased at Ex2. Fluctuations of PET CO2 and BP evoked by exercise were not in accordance with changes in ΔO2 Hb, ΔHHb and rCBF, while BP may affect the forehead skin blood flow. Given that NIRS data are a mixture of skin and brain effects, our results suggest that CMRO2 may differ between the phases in a bout of dynamic exercise. The present study indicates the utility of NIRS to examine the relationship between CMRO2 and rCBF during exercise.- Published
- 2018
- Full Text
- View/download PDF
20. Severe Alcoholic Hepatitis Effectively Treated with Vitamin E as an Add-on to Corticosteroids.
- Author
-
Miyashima Y, Shibata M, Honma Y, Matsuoka H, Hiura M, Abe S, and Harada M
- Subjects
- Adrenal Cortex Hormones administration & dosage, Drug Therapy, Combination, Female, Humans, Japan, Middle Aged, Prognosis, Severity of Illness Index, Vitamin E administration & dosage, Adrenal Cortex Hormones therapeutic use, Hepatitis, Alcoholic drug therapy, Vitamin E therapeutic use
- Abstract
A 49-year-old woman with a history of heavy alcohol drinking was admitted to our hospital due to jaundice and abdominal distention. A blood test showed leukophilia, mild hypoalbuminemia, hyperbilirubinemia, hepatobiliary injury and coagulopathy. Image studies showed an extremely enlarged fatty liver and splenomegaly. The Japan alcoholic hepatitis score and Maddrey's discriminant function were 10 and 54 points, respectively. We diagnosed her with severe alcoholic hepatitis and treated her with corticosteroids, but her liver function did not improve. We therefore administered the vitamin E product tochopheryl acetate (150 mg/day) as an add-on therapy, after which her leukophilia, liver enzymes and coagulopathy improved immediately.
- Published
- 2017
- Full Text
- View/download PDF
21. Bullous Pemphigoid Associated with the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin in a Patient with Liver Cirrhosis Complicated with Rapidly Progressive Hepatocellular Carcinoma.
- Author
-
Harada M, Yoneda A, Haruyama S, Yabuki K, Honma Y, Hiura M, Shibata M, Matsuoka H, and Uchiwa Y
- Subjects
- Aged, Diabetes Mellitus drug therapy, Dipeptidyl-Peptidase IV Inhibitors therapeutic use, Humans, Hypoglycemic Agents adverse effects, Male, Sitagliptin Phosphate therapeutic use, Carcinoma, Hepatocellular pathology, Dipeptidyl-Peptidase IV Inhibitors adverse effects, Liver Cirrhosis pathology, Liver Neoplasms pathology, Pemphigoid, Bullous chemically induced, Sitagliptin Phosphate adverse effects
- Abstract
A 78-year-old man presented with cutaneous blisters of the limbs and abdominal distension. He had been treated for various diseases, including liver cirrhosis. He had begun receiving sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, for diabetes mellitus three years before the hospitalization. A skin biopsy demonstrated bullous pemphigoid. Ultrasonography (US) revealed multiple liver tumors, although he had been receiving regular US studies. We stopped sitagliptin and started insulin and corticosteroids. However, his renal dysfunction progressed, and he died 14 days after the hospitalization. We should therefore be careful of various complications, including bullous pemphigoid and progression of tumors, when using DPP-4 inhibitors.
- Published
- 2017
- Full Text
- View/download PDF
22. Central μ-Opioidergic System Activation Evoked by Heavy and Severe-Intensity Cycling Exercise in Humans: a Pilot Study Using Positron Emission Tomography with 11C-Carfentanil.
- Author
-
Hiura M, Sakata M, Ishii K, Toyohara J, Oda K, Nariai T, and Ishiwata K
- Subjects
- Affect, Carbon Radioisotopes, Exercise Test, Fentanyl administration & dosage, Humans, Limbic System physiology, Male, Pilot Projects, Positron-Emission Tomography, Synaptic Transmission, Young Adult, Exercise physiology, Fatigue, Fentanyl analogs & derivatives, Limbic System diagnostic imaging, Receptors, Opioid, mu physiology
- Abstract
The central opioid receptor system likely contributes to the mechanism underlying the changes in affect elicited by exercise. Our aim was to use positron emission tomography (PET) to test whether exercise intensity influences activation of the μ-opioid receptor system in the brain, and whether changes in opioid receptor activation correlate with exercise-induced changes in affect. 7 healthy young male subjects (23±2 years) performed 20-min constant-load cycling exercises at heavy (ExH) and severe-intensity (ExS), and PET was performed using [
11 C]carfentanil as a tracer before and after each exercise. Exercise elicited the μ-opioidergic system activation in the large areas of the limbic system, particularly in the insular cortex, and cerebellum. Of note, deactivation of the μ-opioidergic system in the pituitary gland was identified as a specific finding in ExS, which evoked a distinctive sensation of fatigue. Within these brain areas, μ-opioid receptor activation correlated positively with increased positive affect (R2 =0.67-0.95) in ExH and negative affect (R2 =0.63-0.77) in ExS. These findings suggest that central μ-opioidergic neurotransmission evoked by continuous exercise is discriminated by work intensity. Notably, we also observed a possible contribution of the central μ-opioidergic system to the development of the sensation of fatigue during exhaustive exercise., (© Georg Thieme Verlag KG Stuttgart · New York.)- Published
- 2017
- Full Text
- View/download PDF
23. Reactivation of Occult Hepatitis B Virus Infection 27 Months after the End of Chemotherapy Including Rituximab for Malignant Lymphoma.
- Author
-
Muraishi J, Shibata M, Honma Y, Hiura M, Abe S, and Harada M
- Subjects
- Aged, Antibodies, Monoclonal, Murine-Derived therapeutic use, Antiviral Agents administration & dosage, Guanine administration & dosage, Guanine therapeutic use, Hepatitis B physiopathology, Hepatitis B Antibodies, Hepatitis B Surface Antigens blood, Hepatitis B e Antigens, Humans, Male, Rituximab administration & dosage, Virus Activation, Antiviral Agents therapeutic use, Guanine analogs & derivatives, Hepatitis B drug therapy, Hepatitis B virus physiology, Lymphoma drug therapy, Rituximab therapeutic use
- Abstract
A 68-year-old man with occult hepatitis B virus (HBV) infection was diagnosed with malignant lymphoma and achieved complete remission after treatment with a chemotherapy regimen including rituximab for 5 months. Entecavir (ETV) was also used during and after chemotherapy and was ended at 14 months after chemotherapy. However, reactivation of HBV was observed in blood tests, which showed not only elevation of HBV-DNA but also HBsAg and HBeAg, at 27 months after the end of chemotherapy. After restarting ETV, the HBV-DNA levels immediately subsided. In addition, anti-HBs became and remained positive at 31 months after chemotherapy. ETV was re-discontinued at 36 months after chemotherapy.
- Published
- 2017
- Full Text
- View/download PDF
24. A novel mutation in the human mineralocorticoid receptor gene in a Japanese family with autosomal-dominant pseudohypoaldosteronism type 1.
- Author
-
Nishizaki Y, Hiura M, Sato H, Ogawa Y, Saitoh A, and Nagasaki K
- Published
- 2016
- Full Text
- View/download PDF
25. A prospective observational study on chemotherapy-induced nausea and vomiting (CINV) in patients with gynecologic cancer by the CINV Study Group of Japan.
- Author
-
Mizuno M, Hiura M, Kikkawa F, Numa F, Yaegashi N, Narahara H, Aoki D, Kimura E, Kato H, Shimokawa M, Sugiyama T, and Kamura T
- Subjects
- Adult, Age Factors, Aged, Aged, 80 and over, Emetics, Female, Humans, Japan, Linear Models, Middle Aged, Morning Sickness epidemiology, Nausea epidemiology, Pregnancy, Prospective Studies, Risk Assessment, Risk Factors, Severity of Illness Index, Visual Analog Scale, Vomiting epidemiology, Antineoplastic Agents adverse effects, Genital Neoplasms, Female drug therapy, Gynecology, Nausea chemically induced, Vomiting chemically induced
- Abstract
Objective: This study was performed to investigate the occurrence of and risk factors for chemotherapy-induced nausea and vomiting (CINV) in patients with gynecologic cancer., Methods: In total, 214 patients with gynecologic cancer who underwent highly emetogenic (HEC) or moderately emetogenic chemotherapy (MEC) were evaluated. We investigated the relationship between CINV and clinical factors and the accuracy of estimation of CINV by medical staff in the acute and late phases. Vomiting was evaluated in terms of frequency, and nausea was evaluated with a 100-mm visual analog scale on days 1 to 7. We also analyzed the risk factors and changes in CINV over time using a generalized linear mixed (GLM) model., Results: The multivariate analysis revealed no significant risk factors for acute CINV. The independent risk factors for delayed nausea were a morning sickness history (odds ratio [OR], 2.687; 95% confidence interval [95% CI], 1.450-4.976; p=0.0017), age (each 1-year increment) (OR, 0.97; 95% CI, 0.944-0.996; p=0.0235), and HEC (OR, 2.134; 95% CI, 1.039-4.383; p=0.0391). The GLM model demonstrated that the independent factors affecting nausea were significant morning sickness (p=0.0101) and HEC (p=0.0136). These data also showed more severe nausea from days 3 to 5, but the negative predictive value for estimation of delayed nausea by medical staff was 57.8%., Conclusion: Our data suggest that improvement of preventive antiemetic administration is needed for patients with risk factors to manage delayed CINV caused by HEC and by MEC., (Copyright © 2015 Elsevier Inc. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
26. Daclatasvir and Asunaprevir Combination Therapy-induced Hepatitis and Cholecystitis with Coagulation Disorder due to Hypersensitivity Reactions.
- Author
-
Miyashima Y, Honma Y, Miyagawa K, Oe S, Senju M, Shibata M, Hiura M, Abe S, and Harada M
- Subjects
- Aged, Antiviral Agents therapeutic use, Asian People, Carbamates, Chemical and Drug Induced Liver Injury blood, Cholecystitis complications, Combined Modality Therapy, Drug Therapy, Combination, Female, Genotype, Hepatitis C, Chronic complications, Humans, Imidazoles administration & dosage, Imidazoles therapeutic use, Isoquinolines administration & dosage, Isoquinolines therapeutic use, Pyrrolidines, Sulfonamides administration & dosage, Sulfonamides therapeutic use, Treatment Outcome, Valine analogs & derivatives, Antiviral Agents adverse effects, Chemical and Drug Induced Liver Injury drug therapy, Cholecystitis chemically induced, Hepatitis C, Chronic drug therapy, Imidazoles adverse effects, Isoquinolines adverse effects, Sulfonamides adverse effects
- Abstract
A 70-year-old woman with chronic hepatitis C was admitted to our hospital due to liver injury, cholecystitis, and disseminated intravascular coagulation with a fever and skin rash. She had been on a combination regimen of daclatasvir and asunaprevir for 2 weeks of a 24-week regimen. Because of the symptoms, laboratory findings, results of a drug-induced lymphocyte stimulation test, and pathological findings of liver biopsy, we diagnosed her with drug-induced liver injury. Although daclatasvir and asunaprevir combination therapy is generally well-tolerated, some serious adverse effects have been reported. Our findings indicate that immunoallergic mechanisms were associated with daclatasvir and asunaprevir-induced liver injury.
- Published
- 2016
- Full Text
- View/download PDF
27. Recognition of infection, status of outpatient treatment, and treatment history before carcinogenesis in patients with viral hepatitis-associated liver cancer.
- Author
-
Shibata M, Minami S, Oe S, Miyagawa K, Honma Y, Onitsuka R, Senju M, Hiura M, Harada R, Abe S, Tabaru A, and Harada M
- Subjects
- Aged, Carcinoma, Hepatocellular therapy, Female, Humans, Liver Neoplasms pathology, Liver Neoplasms therapy, Male, Middle Aged, Outpatients, Risk Factors, Carcinoma, Hepatocellular virology, Hepatitis B complications, Hepatitis C complications, Liver Neoplasms virology
- Abstract
We conducted a survey on the recognition of infection, status of outpatient treatment, and treatment history in hepatitis virus-associated hepatocellular carcinoma patients admitted to our department between 2005 and 2014. We compared these parameters in 75 patients with primary hepatitis B virus-associated hepatocellular carcinoma (HBV-HCC) and 307 patients with hepatitis C virus-associated hepatocellular carcinoma (HCV-HCC). Based on the presence or absence of outpatient treatment in medical institutions at the time of HCC diagnosis, the patients were divided into an outpatient treatment-free group or an outpatient treated group. In addition, the latter group was divided into three subgroups depending on the department consulted:the Department of Internal Medicine group, the Department of Gastroenterology group, and a hepatologist-treated group. Patients in the outpatient treatment-free group accounted for 40.0% of patients with HBV-HCC. In the outpatient treated group (60.0%), 21.3% were treated in the Department of Internal Medicine, 22.7% in the Department of Gastroenterology, and 16.0% were treated by a hepatologist. The percentage of HBV-HCC patients in the outpatient treatment-free group was 1.9 times higher than that in the HCV-HCC group and 0.6-fold higher in the hepatologist-treated group. Of the HBV-HCC patients, non-recognizers who were not diagnosed with a viral infection accounted for 21.3%, and non-outpatients who had not consulted a hospital despite the recognition of infection accounted for 33.3%. These percentages were approximately 2 times higher than in HCV-HCC patients. Of the HBV-HCC patients, 66.7% in the hepatologist-treated group had received nucleic acid analogue preparations. On the other hand, one patient in each of the Department of Internal Medicine and Department of Gastroenterology groups (approximately 6.0%) had received a nucleic acid analogue, lamivudine, despite the appearance of a resistant strain. In the HBV-HCC patients, the proportions of "non-recognizers" and "non-outpatients" were higher than in the HCV-HCC patients, suggesting a lack of appropriate treatment.
- Published
- 2016
- Full Text
- View/download PDF
28. Alleviation mechanisms against hepatocyte oxidative stress in patients with chronic hepatic disorders.
- Author
-
Hiura M, Honma Y, Miyagawa K, Oe S, Shimajiri S, Mihara H, Oe M, Sato-Morita M, Katsuki Y, and Harada M
- Abstract
Aim: Autophagy induction and Mallory-Denk body (MDB) formation have been considered to have cytoprotective effects from cellular stress in liver diseases. We investigated the relations among oxidative stress, autophagy and MDB formation in patients with chronic hepatitis B (CHB), chronic hepatitis C (CHC) and non-alcoholic fatty liver disease (NAFLD) to clarify the alleviation mechanisms against oxidative stress of hepatocytes., Methods: First, we treated cultured cells with proteasome inhibitor (PI) or free fatty acid (FFA) and evaluated endoplasmic reticulum (ER) stress, oxidative stress, ubiquitinated proteins and p62 by western blotting. Then, we used human liver biopsy samples to evaluate oxidative stress, autophagy and MDB formation by immunohistochemical analysis., Results: Treatment with PI or FFA increased ER stress, oxidative stress, ubiquitinated proteins and p62 in cultured cells. Human liver biopsy samples of CHC and NAFLD showed that MDB formed in areas with strong oxidative stress and that the MDB-containing cells circumvented oxidative stress. Keratin 8 (K8) expression was strong in MDB-containing cells in CHC and NAFLD. However, in CHB samples, the expression of K8 was not increased in response to oxidative stress and MDB aggregates did not appear. Aminotransferase values were significantly lower in patients with CHC and NAFLD in whom light chain 3 antibody expression was increased in response to oxidative stress., Conclusion: Strong expression of K8 was considered to be important for MDB formation. MDB protect liver cells from oxidative stress at a cellular level and autophagy reduced hepatic damage when it was induced in the hepatocytes exposed to strong oxidative stress., (© 2015 The Japan Society of Hepatology.)
- Published
- 2015
- Full Text
- View/download PDF
29. Hepatitis A complicated with acute renal failure and high hepatocyte growth factor: A case report.
- Author
-
Oe S, Shibata M, Miyagawa K, Honma Y, Hiura M, Abe S, and Harada M
- Subjects
- Acute Kidney Injury blood, Acute Kidney Injury diagnosis, Acute Kidney Injury therapy, Biomarkers blood, Hepatitis A blood, Hepatitis A diagnosis, Hepatitis A therapy, Hepatitis A Antibodies blood, Humans, Immunoglobulin M blood, Liver Failure, Acute blood, Liver Failure, Acute diagnosis, Liver Failure, Acute therapy, Male, Middle Aged, Time Factors, Treatment Outcome, Up-Regulation, Acute Kidney Injury virology, Hepatitis A complications, Hepatocyte Growth Factor blood, Liver Failure, Acute virology
- Abstract
A 58-year-old man was admitted to our hospital. Laboratory data showed severe liver injury and that the patient was positive for immunoglobulin M anti-hepatitis A virus (HAV) antibodies. He was also complicated with severe renal dysfunction and had an extremely high level of serum hepatocyte growth factor (HGF). Therefore, he was diagnosed with severe acute liver failure with acute renal failure (ARF) caused by HAV infection. Prognosis was expected to be poor because of complications by ARF and high serum HGF. However, liver and renal functions both improved rapidly without intensive treatment, and he was subsequently discharged from our hospital on the 21(st) hospital day. Although complication with ARF and high levels of serum HGF are both important factors predicting poor prognosis in acute liver failure patients, the present case achieved a favorable outcome. Endogenous HGF might play an important role as a regenerative effector in injured livers and kidneys.
- Published
- 2015
- Full Text
- View/download PDF
30. Acute Liver Failure Complicated with Severe Heart Failure.
- Author
-
Minami S, Shibata M, Matsuhashi T, Hiura M, Abe S, and Harada M
- Subjects
- Adult, Female, Fetal Death, Heart Failure etiology, Heart Failure pathology, Heart Ventricles, Hepatitis B complications, Hepatitis B virus isolation & purification, Humans, Liver Failure, Acute virology, Liver Transplantation adverse effects, Pregnancy, Risk Factors, Treatment Outcome, Heart Failure virology, Hepatitis B pathology, Liver Failure, Acute diagnosis
- Abstract
A young pregnant woman was hospitalized due to hepatitis B virus (HBV)-related acute liver failure (ALF). The cardiac function was normal on admission. However, she developed ALF concurrently with a coma and severe cardiac failure. The patient was diagnosed with severe acute cardiomyopathy due to diffuse hypokinesis of the left ventricle wall on ultrasound cardiography. Following intensive treatment, both the liver and cardiac function dramatically recovered. Although some factors, such as HBV, pregnancy and systemic inflammatory response syndrome, are possible causes of acute cardiomyopathy in the present case, ALF itself may be a risk factor for heart failure.
- Published
- 2015
- Full Text
- View/download PDF
31. Hepatic peribiliary cysts with rapidly progressive refractory obstructive jaundice and esophageal varices.
- Author
-
Shibata M, Hiura M, Senju M, Matsuhashi T, Abe S, Morita C, Hayashida K, Tabaru A, and Harada M
- Subjects
- Bile Duct Diseases complications, Fatal Outcome, Humans, Male, Middle Aged, Radiography, Bile Duct Diseases diagnostic imaging, Cysts complications, Cysts diagnostic imaging, Esophageal and Gastric Varices etiology, Jaundice, Obstructive etiology, Liver Cirrhosis, Alcoholic complications
- Abstract
A 54-year-old man with decompensated alcoholic liver cirrhosis presented with acute cholangitis. Although no localized lesions were detected in the liver on contrast-enhanced computed tomography and no risky varices were noted on endoscopy, hepatic peribiliary cysts (HPBCs) developed along the intrahepatic portal vein in the course of only 40 days. Moreover, esophageal varices with the red color sign grew rapidly during the same period, and the patient ultimately died due to rupture. HPBC formation is a rare complication of liver disease, including cirrhosis. Although HPBCs are generally harmless, on rare occasions they may induce the rapid progression of esophageal varices.
- Published
- 2015
- Full Text
- View/download PDF
32. Methotrexate-related primary hepatic lymphoma in a patient with rheumatoid arthritis.
- Author
-
Miyagawa K, Shibata M, Noguchi H, Hayashi T, Oe S, Hiura M, Abe S, and Harada M
- Subjects
- Antirheumatic Agents therapeutic use, Chemical and Drug Induced Liver Injury diagnostic imaging, Female, Humans, Liver Neoplasms diagnostic imaging, Lymphoma, B-Cell diagnostic imaging, Lymphoma, B-Cell drug therapy, Methotrexate therapeutic use, Middle Aged, Positron-Emission Tomography, Tomography, X-Ray Computed, Treatment Outcome, Antirheumatic Agents adverse effects, Arthritis, Rheumatoid drug therapy, Chemical and Drug Induced Liver Injury etiology, Liver Neoplasms chemically induced, Lymphoma, B-Cell chemically induced, Methotrexate adverse effects
- Abstract
A 56-year-old woman with rheumatoid arthritis treated with methotrexate (MTX) was admitted to our hospital due to multiple liver tumors. Contrast-enhanced computed tomography (CT) revealed multiple hypovascular masses, and 18F-fluorodeoxyglucose positron emission tomography CT showed diffuse abnormal accumulation in the liver only. We therefore made a diagnosis of MTX-related primary hepatic lymphoma (MTX-PHL) exhibiting features of diffuse large B-cell lymphoma. Although MTX has been reported to increase the risk of lymphoproliferative disorders, MTX-PHL has not been reported previously. The present case is the first case in which MTX appears to have been involved in the development of PHL.
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.